Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195916 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A Phase 1 study of Solid Tumors and Hematologic Malignancies, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT07195916: Recruiting Phase 1 study of Solid Tumors and Hematologic Malignancies, sponsored by Incyte Corporation.
NCT07195916 is a Phase 1 study of Solid Tumors and Hematologic Malignancies that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 280 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195916, a Phase 1 study of Solid Tumors and Hematologic Malignancies, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Primary Outcome
Toxicities occurring during the first study drug infusion and continues through 28 days as defined in the protocol. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria.
Conditions Studied
Interventions
- DRUG INCA036873
Study Locations (20)
Other
- Cliniques Universitaires Ucl Saint-Luc - Brussels
- Universitair Ziekenhuis Antwerpen - Edegem
- Universitair Ziekenhuis Gent (Uz Gent) - Ghent
- Universitair Ziekenhuis Leuven - Leuven
- Aarhus University Hospital - Aarhus
- Rigshospitalet Uni of Hospital of Copenhagen - Copenhagen
- Aou Policlinico S. Orsola-Malpighi - Bologna
- Fondazione Irccs Istituto Nazionale Dei Tumori - Milan
California
- City of Hope Medical Center - Duarte
- University of California San Diego Medical Center, Moores Cancer Center - La Jolla
Tennessee
- Scri Oncology Partners - Nashville
- Vanderbilt Medical Center - Nashville
Michigan
- University of Michigan - Ann Arbor
Nebraska
- The University of Nebraska Medical Center - Omaha
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Md Anderson Cancer Center - Houston
New South Wales
- Macquarie University Hospital - Sydney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-01-08 |
| Est. Completion | 2028-08-18 |
| Phase | Phase 1 |
What NCT07195916 shows while recruiting
NCT07195916 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which INCA036873 is the first listed.
NCT07195916 names 20 study sites across 11 states, led by Other, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07195916 about?
NCT07195916 is a clinical study titled "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies". A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
What is the current status of trial NCT07195916?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2026-01-08. Estimated completion is 2028-08-18.
What conditions does trial NCT07195916 study?
This clinical trial studies the following conditions: Solid Tumors, Hematologic Malignancies.
What interventions are being tested in trial NCT07195916?
The interventions under investigation include: INCA036873 (DRUG).
Who is sponsoring clinical trial NCT07195916?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195916 being conducted?
This trial has 20 study locations across California, Michigan, Nebraska, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07195916's enrollment target sits among peer trials
280 20th of 125 higher than 106 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI